Cargando…

HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells

BACKGROUND: Heregulin (HRG; also known as neuregulin) is a ligand for ErbB3. One of its isotypes, HRG-β1, binds to ErbB3 and forms heterodimers with other ErbB family members, thereby enhancing the proliferation and tumorigenesis of breast cancer cells. HRG stimulation may contribute to the progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jinkyoung, Jeong, Hoiseon, Lee, Youngseok, Kim, Chungyeul, Kim, Hankyeom, Kim, Aeree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750857/
https://www.ncbi.nlm.nih.gov/pubmed/23937725
http://dx.doi.org/10.1186/1471-2407-13-383
_version_ 1782281487972827136
author Kim, Jinkyoung
Jeong, Hoiseon
Lee, Youngseok
Kim, Chungyeul
Kim, Hankyeom
Kim, Aeree
author_facet Kim, Jinkyoung
Jeong, Hoiseon
Lee, Youngseok
Kim, Chungyeul
Kim, Hankyeom
Kim, Aeree
author_sort Kim, Jinkyoung
collection PubMed
description BACKGROUND: Heregulin (HRG; also known as neuregulin) is a ligand for ErbB3. One of its isotypes, HRG-β1, binds to ErbB3 and forms heterodimers with other ErbB family members, thereby enhancing the proliferation and tumorigenesis of breast cancer cells. HRG stimulation may contribute to the progression of epithelial–mesenchymal transition (EMT) and tumor metastasis in breast cancer. Majority of studies regarding EMT has been concentrated on TGF-β signaling. Therefore, we investigated whether the HRG-β1 and ErbB3 activate Smad2 signaling during process of EMT in breast cancer cells. METHODS: The SK-BR-3 and MCF7 breast cancer cell lines were used. The expressions of phospho-Smad2 and EMT markers were observed by western blotting and immunofluorescence assays after treatment with HRG-β1. The cell motility and invasiveness were determined by wound healing and matrigel invasion assays. Smad2 and ErbB3 small interfering RNA (siRNA) transfections were performed to assess the involvement of ErbB3 and Smad2 in HRG-β1-induced EMT. RESULTS: HRG-β1 induced EMT through activation of Smad2. The expression of E-cadherin was decreased after HRG-β1 treatment, while the expressions of Snail, vimentin, and fibronectin were increased. The HRG-β1-induced expressions of Snail, vimentin, and fibronectin, and nuclear colocalization of phospho-Smad2 and Snail were inhibited by pretreatment with a PI3k inhibitor, LY294002, or two phospho-Smad2 inhibitors, PD169316 or SB203580 and cancer cell migration by HRG-β1 was inhibited. Knockdown of Smad2 by siRNA transfection suppressed the expressions of Snail and fibronectin in response to HRG-β1 stimulation and knockdown of ErbB3 suppressed the expressions of phospho-Smad2, Snail, and fibronectin induced by HRG-β1, whereas E-cadherin was increased compared with control siRNA-transfected cells. Knockdown of ErbB3 and Smad2 also decreased SK-BR-3 and MCF7 cell invasion. CONCLUSIONS: Our data suggest that HRG-β1 and ErbB3 induce EMT, cancer cell migration and invasion through the PI3k/Akt-phospho-Smad2-Snail signaling pathway in SK-BR-3 and MCF7 breast cancer cells.
format Online
Article
Text
id pubmed-3750857
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37508572013-08-24 HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells Kim, Jinkyoung Jeong, Hoiseon Lee, Youngseok Kim, Chungyeul Kim, Hankyeom Kim, Aeree BMC Cancer Research Article BACKGROUND: Heregulin (HRG; also known as neuregulin) is a ligand for ErbB3. One of its isotypes, HRG-β1, binds to ErbB3 and forms heterodimers with other ErbB family members, thereby enhancing the proliferation and tumorigenesis of breast cancer cells. HRG stimulation may contribute to the progression of epithelial–mesenchymal transition (EMT) and tumor metastasis in breast cancer. Majority of studies regarding EMT has been concentrated on TGF-β signaling. Therefore, we investigated whether the HRG-β1 and ErbB3 activate Smad2 signaling during process of EMT in breast cancer cells. METHODS: The SK-BR-3 and MCF7 breast cancer cell lines were used. The expressions of phospho-Smad2 and EMT markers were observed by western blotting and immunofluorescence assays after treatment with HRG-β1. The cell motility and invasiveness were determined by wound healing and matrigel invasion assays. Smad2 and ErbB3 small interfering RNA (siRNA) transfections were performed to assess the involvement of ErbB3 and Smad2 in HRG-β1-induced EMT. RESULTS: HRG-β1 induced EMT through activation of Smad2. The expression of E-cadherin was decreased after HRG-β1 treatment, while the expressions of Snail, vimentin, and fibronectin were increased. The HRG-β1-induced expressions of Snail, vimentin, and fibronectin, and nuclear colocalization of phospho-Smad2 and Snail were inhibited by pretreatment with a PI3k inhibitor, LY294002, or two phospho-Smad2 inhibitors, PD169316 or SB203580 and cancer cell migration by HRG-β1 was inhibited. Knockdown of Smad2 by siRNA transfection suppressed the expressions of Snail and fibronectin in response to HRG-β1 stimulation and knockdown of ErbB3 suppressed the expressions of phospho-Smad2, Snail, and fibronectin induced by HRG-β1, whereas E-cadherin was increased compared with control siRNA-transfected cells. Knockdown of ErbB3 and Smad2 also decreased SK-BR-3 and MCF7 cell invasion. CONCLUSIONS: Our data suggest that HRG-β1 and ErbB3 induce EMT, cancer cell migration and invasion through the PI3k/Akt-phospho-Smad2-Snail signaling pathway in SK-BR-3 and MCF7 breast cancer cells. BioMed Central 2013-08-12 /pmc/articles/PMC3750857/ /pubmed/23937725 http://dx.doi.org/10.1186/1471-2407-13-383 Text en Copyright © 2013 Kim et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kim, Jinkyoung
Jeong, Hoiseon
Lee, Youngseok
Kim, Chungyeul
Kim, Hankyeom
Kim, Aeree
HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
title HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
title_full HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
title_fullStr HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
title_full_unstemmed HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
title_short HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
title_sort hrg-β1-driven erbb3 signaling induces epithelial–mesenchymal transition in breast cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750857/
https://www.ncbi.nlm.nih.gov/pubmed/23937725
http://dx.doi.org/10.1186/1471-2407-13-383
work_keys_str_mv AT kimjinkyoung hrgb1drivenerbb3signalinginducesepithelialmesenchymaltransitioninbreastcancercells
AT jeonghoiseon hrgb1drivenerbb3signalinginducesepithelialmesenchymaltransitioninbreastcancercells
AT leeyoungseok hrgb1drivenerbb3signalinginducesepithelialmesenchymaltransitioninbreastcancercells
AT kimchungyeul hrgb1drivenerbb3signalinginducesepithelialmesenchymaltransitioninbreastcancercells
AT kimhankyeom hrgb1drivenerbb3signalinginducesepithelialmesenchymaltransitioninbreastcancercells
AT kimaeree hrgb1drivenerbb3signalinginducesepithelialmesenchymaltransitioninbreastcancercells